Singapore Stocks to Watch: SIA, SIA Engineering, F&N, Silverlake, Jiutian Chemical

TigerNews_SG
02-16

THE following companies saw new developments that may affect trading of their securities on Friday (Feb 16):

$SINGAPORE Airlines(C6L.SI)$ (SIA) recorded a year-on-year, 14.4 per cent rise in group passenger traffic to 12.6 billion for January 2024, it said on Thursday (Feb 15).

Within the group, the flagship airline’s revenue passenger-kilometres rose 14.3 per cent to 9.6 billion from 8.4 billion year on year. Passenger traffic, expressed as revenue passenger-km, indicates the number of passengers carried multiplied by the distance flown.

Passenger capacity across the group rose 16.5 per cent on-year to 14.7 billion from 12.7 billion, outpacing January’s revenue passenger-km due to the shift in the Chinese New Year to February.

$Fraser and Neave(F99.SI)$ (F&N) on Thursday (Feb 15) announced that its Malaysian unit Fraser & Neave Holdings Berhad (F&NHB) has agreed, through a subsidiary, to lease an industrial land parcel in Cambodia for a total consideration of US$3.9 million.

Bursa Malaysia-listed F&NHB intends to build a dairy manufacturing facility on the 32,200 square metre (sq m) land parcel, which it has leased for 50 years starting from Feb 1, 2024, noted F&N in the announcement. The statement was also filed on the Malaysian bourse.

$SIA Engineering Company(S59.SI)$ (SIAEC) has reported net profit of $26.9 million for the 3QFY2023/2024 ended Dec 31, 2023, more than double its net profit of $12.8 million in the corresponding period last year.

Net profit for the 9MFY2022/2023 also increased 90.3% y-o-y to $86.2 million.

Revenue for 3QFY2023/2024 improved 40.2% y-o-y to $291.7 million while group expenditure rose at a lower rate of 33.8% y-o-y to $295.1 million mainly due to an increase in manpower costs and material costs.

$Jiutian Chemical Group(C8R.SI)$ has issued a profit warning for FY2023 ended Dec 31, 2023, saying it expects to announce a net loss for the full-year period. 

In a Feb 15 bourse filing, its Board of Directors says this is mainly due to a decline in the average selling prices of its main products — dimethylformamide and methylamine — arising from an industry-wide softening of demand and significant production capacity added by a new competitor since 4Q2022. 

The competitor is Jiangxi Xinlianxin Chemical Industry, a subsidiary of Henan XinLianXin Chemical Group Co. Ltd.

$Silverlake Axis(5CP.SI)$ has reported earnings of RM89.3 million ($25.2 million) for the 1HFY2024 ended Dec 31, 2023, an 11% decrease compared to its earnings of RM99.7 million in the corresponding period last year.

Revenue in the half-year period increased 1% y-o-y to RM397.4 million while cost of sales increased 9% y-o-y to RM177.2 million.

The company's total recurring revenue, which gives better earnings visibility and accounts for 75% of its overall revenue, increased 7% y-o-y to RM298.8 million.

$(C8R.SI)$ $(5CP.SI)$ $(S59.SI)$ $(C6L.SI)$ $(F99.SI)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment
1